Testing revumenib for active myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests an experimental drug called revumenib, either alone or combined with a JAK inhibitor, for people with myelofibrosis that is still active despite standard treatment. The goal is to see if revumenib can better control symptoms, reduce spleen size, or improve blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a confirmed diagnosis of myelofibrosis (including types linked to other blood disorders).
- Your disease is considered intermediate-1 or higher risk, meaning it's active enough to need treatment.
- If you are not currently on a JAK inhibitor, you must have tried at least one and it stopped working or caused side effects. If you are on one now, you can stay on it.
- You have symptoms or signs like an enlarged spleen (felt below your ribs), bothersome symptoms (like fatigue, fever, night sweats), or need regular blood transfusions.
- Your liver, kidney, heart function, and blood cell counts must be at safe levels based on recent lab work.
- You must not have certain serious heart problems, uncontrolled infections, or other cancers in the last 3 years (except minor skin or local cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This Phase 2 trial tests whether elritercept, given alone or together with ruxolitinib, can improve symptoms and disease control in adults with myelofibrosis. It may help people who have anemia and either cannot tolerate, can’t get enough benefit from, or are already using ruxolitinib.
This trial tests an experimental drug called AJ1-11095 for people with myelofibrosis who no longer respond to a type of JAK2 inhibitor. It aims to see if the drug can shrink the spleen, improve symptoms, and be safe.
This trial tests two oral medications, momelotinib and ruxolitinib, to see which works better for people with newly diagnosed myelofibrosis who also have low blood cell counts. You may be able to join if your spleen is enlarged and you haven't had prior treatment with certain drugs.
This trial tests a new drug called RVU120 for people with myelofibrosis that has not responded well to standard JAK inhibitor treatment. It aims to shrink the spleen and improve symptoms.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.